ARCHIVES

ODAC votes 9-6 in favor of Clolar for pediatric acute lymphoblastic leukemia, but votes against Marqibo for non-Hodgkin’s lymphoma.

This article is from The Cancer Letter archive.

Vol. 30 No. 46 | December 10, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Congress Asked To Investigate Dieldrin Danger; Harvard’s Rosenberg To Be NCI Surgery Chief

April 5, 1974

In Brief: Magnuson Subcommittee Increases NCI, NIH Budgets Despite Trimming Labor-HEW Bill By $250 Million

August 23, 1974

NIH COI Rule Mandates More Disclosure, Leaves Institutions In Charge Of Ethics Of Extramural Researchers

September 16, 2011

In Brief: Unsolicited Proposals ‘Very Valuable,” DeVita Says, Asks Investigators To Keep Channel Open

April 18, 1975

Childhood cancer Death Rates Decline, Incidence Stable, NCI Says In Report

July 30, 1999

In Brief: Interim Dean Henney Looking for Cancer Center Director; Shingleton Gets James Ewing Award

June 10, 1988